Enanta Pharmaceuticals (ENTA) Income from Continuing Operations (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Income from Continuing Operations data on file, last reported at 13091000.0 in Q1 2026.

• Quarterly Income from Continuing Operations rose 42.19% year-over-year to 13091000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 61984000.0 (up 35.71% YoY) and the FY2025 annual result came in at 81889000.0, up 29.43% from the prior year.
• Income from Continuing Operations slipped to 13091000.0 in Q1 2026, from 11938000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 11938000.0 in Q4 2025 to a low of 39065000.0 in Q2 2023.
• A 5-year average of 26229235.29 and a median of 26348000.0 in 2022 frame the typical range for Income from Continuing Operations.
• The widest YoY moves for Income from Continuing Operations: up 67.83% in 2022, down 31.95% in 2022.
• Tracing ENTA's Income from Continuing Operations over 5 years: stood at 28986000.0 in 2022, then decreased by 15.25% to 33407000.0 in 2023, then surged by 33.28% to 22290000.0 in 2024, then surged by 46.44% to 11938000.0 in 2025, then slipped by 9.66% to 13091000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 13091000.0 (Q1 2026), 11938000.0 (Q4 2025), and 18700000.0 (Q3 2025), per Business Quant data.